Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27781702 | 0.78 | ALDH1A1 (0.41) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL1120209 | 0.74 | — | — | |
| SCHEMBL2485440 | 0.74 | — | — | |
| SCHEMBL23193783 | 0.72 | ALDH1A1 (0.30) | ALDH1A1MAPT | |
| SCHEMBL10308597 | 0.70 | TSHR (0.42) | TSHRALDH1A1ALOX15CHRM2CHRM4 | |
| SCHEMBL5225784 | 0.70 | TSHR (0.42) | TSHRALDH1A1ALOX15CHRM2CHRM4 | |
| SCHEMBL11659865 | 0.69 | — | — | |
| SCHEMBL3975509 | 0.68 | — | — | |
| SCHEMBL1442538 | 0.67 | TSHR (0.50) | TSHRALDH1A1ALOX15CHRM2CHRM4 | |
| SCHEMBL3945787 | 0.67 | TSHR (0.50) | TSHRALDH1A1ALOX15CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376524-B1 | DERIVATIVES OF CYCLOSPORIN A | CYPRALIS LTD (GB) | 2017-03-15 | — | — | EP | disclosed |
| US-8551952-B2 | Methods for the treatment and prevention of ocular disorders | SCYNEXIS, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8536114-B2 | Macrocycles | SCYNEXIS, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20120270804-A1 | METHODS FOR THE TREATMENT AND PREVENTION OF OCULAR DISORDERS | HOUCK DAVID RENWICK (US) | 2012-10-25 | — | — | US | disclosed |
| US-8188052-B2 | Method for the treatment and prevention of ocular disorders | SCYNEXIS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2023918-B1 | CYCLOSPORINS FOR THE TREATMENT AND PREVENTION OF OCULAR DISORDERS | SCYNEXIS INC (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100173836-A1 | NOVEL MACROCYCLES | CYPRALIS LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100062975-A1 | METHOD FOR THE TREATMENT AND PREVENTION OF OCULAR DISORDERS | SCYNEXIS, INC. | 2010-03-11 | — | — | US | disclosed |
| EP-2023918-A2 | METHOD FOR THE TREATMENT AND PREVENTION OF OCULAR DISORDERS | Scynexis, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007136759-A2 | METHOD FOR THE TREATMENT AND PREVENTION OF OCULAR DISORDERS | SCYNEXIS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100062975-A1 | METHOD FOR THE TREATMENT AND PREVENTION OF OCULAR DISORDERS | ALDH1A2, ALDH1A3, ADH1B | TSHR 814/4885ALDH1A1 80/4885ALOX15 905/4885 |
| US-20100173836-A1 | NOVEL MACROCYCLES | CCNB2, CYP1B1, CCKBR | TSHR 471/4885ALDH1A1 641/4885ALOX15 3560/4885 |
| US-20120270804-A1 | METHODS FOR THE TREATMENT AND PREVENTION OF OCULAR DISORDERS | ALDH1A2, ALDH1A3, EYA3 | TSHR 1080/4885ALDH1A1 63/4885ALOX15 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.